

**Supplemental Table 1:** Characteristics of clinical trials used in comparison to present study.

Author, Year Published	Age Range	<i>n</i> (for dose 1)	Study Site	Study Design
Marshall, 2013	$\geq 18 \leq 40$	60	Australia	phase 2, single-arm, open-label study (healthy adults)
Richmond, 2012	$\geq 11 \leq 18$	197	Europe, Australia	randomized, single-blind, placebo-controlled study (dose-escalation trial)
Senders, 2016	$\geq 11 < 18$	985	U.S.	randomized, active-controlled, observed-blinded study (safety when co-administered with HPV)
Sheldon, 2012	$\geq 18 \leq 40$	12	U.S.	randomized, open-label, active- and placebo-controlled study in adults (dose-escalation trial)
Vesikari, 2016	$\geq 11 \leq 19$	412	Europe	Randomized, placebo-controlled, single-blind study (dose-escalation trial)
Reiner, 2016	$\geq 18 \leq 65$	13	U.S.	single-arm, open-label study (safety in laboratory staff working with <i>N. meningitidis</i> )